医学
类风湿性关节炎
逐渐变细
巨细胞动脉炎
托珠单抗
羟基氯喹
生物制剂
依那西普
免疫学
内科学
皮肤病科
血管炎
疾病
2019年冠状病毒病(COVID-19)
传染病(医学专业)
计算机图形学(图像)
计算机科学
作者
Frank Buttgereit,Andriko Palmowski
出处
期刊:Joint Bone Spine
[Elsevier BV]
日期:2021-10-01
卷期号:89 (1): 105285-105285
被引量:12
标识
DOI:10.1016/j.jbspin.2021.105285
摘要
Glucocorticoids (GCs) remain regularly used drugs in patients with chronic inflammatory rheumatic diseases. As long-term intake at high dosages is associated with harm, it is generally advised that GCs be tapered and stopped. However, most recommendations concerning tapering have been eminence- or consensus-based. In this narrative review, we present novel data from recent studies (SEMIRA, CORTICOLUP, and GiACTA) shedding light from different angles on the effects of tapering GCs in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and giant cell arteritis (GCA). In RA and SLE, our main findings comprise that (a) the majority of RA and SLE patients can successfully taper their GC, but that (b) tapering increases the risk of flare. In GCA, tocilizumab was shown to be a potent GC-sparing agent. Finally, we also present exemplary tapering schemes for RA, SLE, and GCA, although different tapering regimens have not yet been sufficiently compared in randomized trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI